NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis $0.81 0.00 (0.00%) (As of 09/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Xilio Therapeutics alerts: Email Address About Xilio Therapeutics Stock (NASDAQ:XLO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xilio Therapeutics alerts:Sign Up Key Stats Today's Range$0.74▼$0.8550-Day Range$0.74▼$1.0252-Week Range$0.49▼$2.89Volume442,855 shsAverage Volume589,814 shsMarket Capitalization$29.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewXilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More… Bill Gates’ Next Big Thing: “Exegesis AI” (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate Xilio Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 40th PercentileXilio Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 747th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Xilio Therapeutics.Read more about Xilio Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.26) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xilio Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.13% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.13% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.28 News SentimentXilio Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xilio Therapeutics' insider trading history. Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address XLO Stock News HeadlinesShort Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Drops By 72.1%September 13, 2024 | americanbankingnews.comXilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 28, 2024 | globenewswire.com Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!September 18, 2024 | Paradigm Press (Ad)XLO Stock Earnings: Xilio Therapeutics Misses EPS for Q2 2024August 8, 2024 | investorplace.comXilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | finanznachrichten.deXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.June 13, 2024 | globenewswire.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024May 14, 2024 | investorplace.comSee More Headlines XLO Stock Analysis - Frequently Asked Questions How have XLO shares performed this year? Xilio Therapeutics' stock was trading at $0.55 at the beginning of the year. Since then, XLO stock has increased by 47.3% and is now trading at $0.81. View the best growth stocks for 2024 here. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.01. The firm had revenue of $2.36 million for the quarter, compared to the consensus estimate of $30 million. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an IPO on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Xilio Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.80%) and XTX Topco Ltd (0.08%). Insiders that own company stock include Gilead Sciences, Inc, Venture Fund Xi LP Atlas, Bain Capital Life Sciences Inv and Rock Springs Capital Managemen. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees73Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,400,000.00 Net MarginsN/A Pretax Margin-2,780.27% Return on Equity-173.95% Return on Assets-83.00% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual Sales$2.36 million Price / Sales11.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.57Miscellaneous Outstanding Shares36,912,000Free Float34,993,000Market Cap$28.07 million OptionableNot Optionable Beta-0.10 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:XLO) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersJoin Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading ...Monument Traders Alliance | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredI’m giving you the name of this investment for freeNow that the Federal Reserve lowered interest rates, this investment could easily go up 50%.Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredKamala Harris To Tank the Market?URGENT ELECTION MELTDOWN WARNING From the former CIA advisor who predicted President Trump’s win in 2016…Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.